In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yondelis Experience Highlights EMEA Issues

Executive Summary

The European regulators' rejection of PharmaMar's lead anti-cancer drug Yondelis in November 2003 was a significant setback for Spain's flagship biotech. But the decision was close; some experts still feel the drug should have been approved. Indeed, although critics claim PharmaMar could have done more to ensure its trial design was satisfactory, the experience highlights weaknesses in Europe's centralized drug approvals procedure of which other firms should be aware. All the more so since the centralized route will likely soon be compulsory not only for biologics, but also for all products in cancer, HIV/AIDS, neurodegenerative disease and diabetes, and all designated orphan drugs.
Advertisement

Related Content

Spain's First Biotech VC
Transatlantic Tit For Tat

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004844

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel